vs

Side-by-side financial comparison of Invivyd, Inc. (IVVD) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

PEDEVCO CORP is the larger business by last-quarter revenue ($23.1M vs $17.2M, roughly 1.3× Invivyd, Inc.). PEDEVCO CORP runs the higher net margin — -36.8% vs -64.3%, a 27.5% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs 24.5%).

Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

IVVD vs PED — Head-to-Head

Bigger by revenue
PED
PED
1.3× larger
PED
$23.1M
$17.2M
IVVD
Growing faster (revenue YoY)
PED
PED
+93.7% gap
PED
118.2%
24.5%
IVVD
Higher net margin
PED
PED
27.5% more per $
PED
-36.8%
-64.3%
IVVD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVVD
IVVD
PED
PED
Revenue
$17.2M
$23.1M
Net Profit
$-11.1M
$-8.5M
Gross Margin
Operating Margin
-73.0%
-21.3%
Net Margin
-64.3%
-36.8%
Revenue YoY
24.5%
118.2%
Net Profit YoY
40.0%
-243.5%
EPS (diluted)
$0.02
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVVD
IVVD
PED
PED
Q4 25
$17.2M
$23.1M
Q3 25
$13.1M
$7.0M
Q2 25
$11.8M
$7.0M
Q1 25
$11.3M
$8.7M
Q4 24
$13.8M
$10.6M
Q3 24
$9.3M
$9.1M
Q2 24
$2.3M
$11.8M
Q1 24
$0
$8.1M
Net Profit
IVVD
IVVD
PED
PED
Q4 25
$-11.1M
$-8.5M
Q3 25
$-10.5M
$-325.0K
Q2 25
$-14.7M
$-1.7M
Q1 25
$-16.3M
$140.0K
Q4 24
$-18.4M
$5.9M
Q3 24
$-60.7M
$2.9M
Q2 24
$-47.2M
$2.7M
Q1 24
$-43.5M
$773.0K
Operating Margin
IVVD
IVVD
PED
PED
Q4 25
-73.0%
-21.3%
Q3 25
-84.0%
-12.0%
Q2 25
-127.8%
-32.2%
Q1 25
-149.7%
1.7%
Q4 24
-139.1%
-12.9%
Q3 24
-670.0%
31.3%
Q2 24
-2175.2%
22.3%
Q1 24
7.6%
Net Margin
IVVD
IVVD
PED
PED
Q4 25
-64.3%
-36.8%
Q3 25
-79.7%
-4.7%
Q2 25
-124.4%
-24.0%
Q1 25
-144.1%
1.6%
Q4 24
-133.5%
56.0%
Q3 24
-653.1%
32.2%
Q2 24
-2086.9%
22.7%
Q1 24
9.5%
EPS (diluted)
IVVD
IVVD
PED
PED
Q4 25
$0.02
$-2.23
Q3 25
$-0.06
$0.00
Q2 25
$-0.12
$-0.02
Q1 25
$-0.14
$0.00
Q4 24
$-0.14
$2.69
Q3 24
$-0.51
$0.03
Q2 24
$-0.40
$0.03
Q1 24
$-0.38
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVVD
IVVD
PED
PED
Cash + ST InvestmentsLiquidity on hand
$226.7M
$3.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$241.5M
$207.4M
Total Assets
$276.9M
$375.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVVD
IVVD
PED
PED
Q4 25
$226.7M
$3.2M
Q3 25
$85.0M
$10.9M
Q2 25
$34.9M
$8.5M
Q1 25
$48.1M
$10.4M
Q4 24
$69.3M
$4.0M
Q3 24
$106.9M
$4.6M
Q2 24
$147.9M
$6.1M
Q1 24
$189.4M
$13.3M
Stockholders' Equity
IVVD
IVVD
PED
PED
Q4 25
$241.5M
$207.4M
Q3 25
$93.1M
$115.4M
Q2 25
$42.8M
$115.2M
Q1 25
$54.1M
$116.2M
Q4 24
$67.5M
$115.6M
Q3 24
$83.2M
$106.5M
Q2 24
$140.6M
$103.2M
Q1 24
$178.5M
$100.0M
Total Assets
IVVD
IVVD
PED
PED
Q4 25
$276.9M
$375.9M
Q3 25
$139.2M
$135.9M
Q2 25
$89.1M
$136.8M
Q1 25
$103.7M
$145.6M
Q4 24
$129.5M
$128.3M
Q3 24
$161.9M
$114.3M
Q2 24
$177.3M
$111.0M
Q1 24
$215.5M
$118.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVVD
IVVD
PED
PED
Operating Cash FlowLast quarter
$-15.5M
$-2.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVVD
IVVD
PED
PED
Q4 25
$-15.5M
$-2.1M
Q3 25
$-8.3M
$7.4M
Q2 25
$-13.3M
$-420.0K
Q1 25
$-21.1M
$5.9M
Q4 24
$-37.6M
$4.2M
Q3 24
$-41.1M
$8.3M
Q2 24
$-41.6M
$4.6M
Q1 24
$-50.2M
$-4.3M
Free Cash Flow
IVVD
IVVD
PED
PED
Q4 25
Q3 25
Q2 25
$-13.3M
Q1 25
$-21.3M
Q4 24
$-37.6M
Q3 24
$-41.1M
Q2 24
Q1 24
$-50.4M
FCF Margin
IVVD
IVVD
PED
PED
Q4 25
Q3 25
Q2 25
-112.9%
Q1 25
-188.2%
Q4 24
-272.2%
Q3 24
-441.6%
Q2 24
Q1 24
Capex Intensity
IVVD
IVVD
PED
PED
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
1.3%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.0%
Q1 24
Cash Conversion
IVVD
IVVD
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons